trending Market Intelligence /marketintelligence/en/news-insights/trending/qnFdv1-MLN3LySzasLD1rQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Avenue Therapeutics files for US FDA approval of injectable opioid pain drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Avenue Therapeutics files for US FDA approval of injectable opioid pain drug

Avenue Therapeutics Inc. submitted an application seeking U.S. approval of its formulation of injectable tramadol, an opioid medicine that has been in use for decades and sold under many brand names worldwide.

Avenue's President and CEO Lucy Lu said intravenous tramadol is a potential alternative that could reduce the use of conventional opioids for pain management.

The New York-based specialty pharmaceutical company said the new drug application was backed by data from two phase 3 studies of the intravenous — administered into the veins — formulation of tramadol that showed that the drug helped reduce pain in certain patients following surgery.

Avenue noted in its Dec. 11 press release that the filing also included findings from a study that suggests that abuse with tramadol was infrequent in terms of absolute number and in comparison to other prescription opioids. Abuse of injectable tramadol, in countries where it is available, was also found to be uncommon compared to oral tramadol.

The U.S. is reeling under an opioid epidemic, which kills about 130 Americans each day, with major healthcare companies facing lawsuits from across the country over their alleged role in flaring up the crisis.